The inverse association between serum 25-hydroxyvitamin D and mortality may be modified by vitamin A status and use of vitamin A supplements

Schmutz, Einat Avital ; Zimmermann, Michael Bruce ; Rohrmann, Sabine

Abstract: BACKGROUND Low serum 25-hydroxyvitamin D [25(OH)D] levels have been associated with higher risk of many diseases that affect mortality, including cardiovascular disease (CVD) and cancer. The inverse association between serum 25(OH)D and mortality may be modified by excess circulating vitamin A, due to interactions of vitamin A at the level of the vitamin D nuclear receptor. In this prospective cohort study, we investigated whether the association of 25(OH)D with all-cause, cancer, and CVD mortality was modified by circulating vitamin A or preformed vitamin A intake from supplements. METHODS We analyzed 15,998 adults in the Third National Health and Nutrition Examination Survey (NHANES III), 1988-1994. Mortality data for all-cause (n = 3890), cancer (n = 844), and CVD mortality (n = 1715) were assessed through December 2006. Serum 25(OH)D was measured using a radioimmunoassay kit, vitamin A biomarkers were measured by HPLC, and information on supplement use was obtained by self-report. Multivariable hazard ratios (HRs) and corresponding 95 % confidence intervals (CI) were estimated by proportional hazards regression. RESULTS Serum 25(OH)D was significantly inversely associated with all-cause mortality (HR 0.93, 95 % CI 0.89, 0.97, per 10 ng/mL increase) and also with CVD mortality and mortality due to non-cancer/non-cardiovascular causes, but not with cancer mortality. The observed inverse associations remained statistically significant only among participants with serum retinyl esters <7.0 g/dL. High intake (>5000 IU/day) of preformed vitamin A from supplements attenuated the inverse association of 25(OH)D with overall mortality. The observed interactions were not statistically significant. CONCLUSIONS 25(OH)D was inversely associated with overall mortality, CVD mortality, and mortality due to non-cancer/non-CVD causes, but not with cancer mortality. A possible interaction between vitamin A exposure and 25(OH)D concentration appears to be associated with an attenuation of the inverse association between risk of death and quartile of 25(OH)D concentration.

DOI: https://doi.org/10.1007/s00394-015-0860-y

Title

The inverse association between serum 25-hydroxyvitamin D and mortality may be modified by vitamin A status and use of vitamin A supplements

Authors

Einat Avital Schmutz[1], Michael Bruce Zimmermann[1], Sabine Rohrmann[2]

Affiliations

[1]Laboratory of Human Nutrition, Institute of Food, Nutrition and Health, ETH Zurich, Zurich, Switzerland

[2] Department of Chronic Disease Epidemiology, Epidemiology, Biostatistics and Prevention Institute (EBPI), University of Zurich, Zurich, Switzerland

Corresponding Author

Sabine Rohrmann

Institute of Social and Preventive Medicine

University of Zurich

Hirschengraben 84

8001 Zurich

Switzerland

e-mail sabine.rohrmann@ifspm.uzh.ch

phone +41 44 634 5256

ABSTRACT

Background: Low serum 25-hydroxyvitamin D [25(OH)D] levels have been associated with higher risk of many diseases that affect mortality, including cardiovascular disease and cancer. The inverse association between serum 25(OH)D and mortality may be modified by excess circulating vitamin A, due to interactions of vitamin A at the level of the vitamin D nuclear receptor. In this prospective cohort study, we investigated whether the association of 25(OH)D with all-cause, cancer and cardiovascular disease mortality was modified by circulating vitamin A or preformed vitamin A intake from supplements.

Methods: We analyzed 15,998 adults in the Third National Health and Nutrition Examination Survey (NHANES III), 1988-1994. Mortality data for all-cause (n=3890), cancer (n=844) and CVD mortality (n=1715) was assessed through December 2006. Serum 25(OH)D was measured using a radio-immunoassay kit, vitamin A biomarkers were measured by HPLC, and information on supplement use was obtained by self-report. Multivariable hazard ratios (HRs) and corresponding 95% confidence intervals (CI) were estimated by proportional hazards regression.

Results: Serum 25(OH)D was significantly inversely associated with all-cause mortality (HR: 0.93, 95% CI 0.89, 0.97, per 10 ng/mL increase), and also with cardiovascular disease (CVD) mortality and mortality due to non-cancer/non-cardiovascular causes, but not with cancer mortality. The observed inverse associations remained statistically significant only among participants with serum retinyl esters <7.0 μg/dL. High intake (>5000IU/day) of preformed vitamin A from supplements attenuated the inverse association of 25(OH)D with overall mortality. The observed interactions were not statistically significant.

Conclusions: 25(OH)D was inversely associated with overall mortality, CVD mortality and mortality due to non-cancer/non-CVD causes, but not with cancer mortality. A possible interaction between vitamin A exposure and 25(OH)D concentration appears to be associated with an attenuation of the inverse association between risk of death and quartile of 25(OH)D concentration.

INTRODUCTION

Vitamin D is a fat-soluble steroid molecule that plays a pivotal role in the maintenance of musculoskeletal health. For several years, however, vitamin D is emerging as a critical regulator of the pathogenetic process of a number of non-skeletal diseases such as cardiovascular [1] and autoimmune disorders [2,3], infections [4,5] and several types of cancers [6,7], indicating a possible pleiotropic effect across extraskeletal systems. Accordingly, it was suggested that low levels of vitamin D may increase the risk of death due to the wide ranging anti-inflammatory and immune modulating effects [8,9]. A recently published meta-analysis of observational and trial data relating vitamin D to the risk of all-cause and cause-specific mortality found inverse associations of circulating 25-hydroxyvitamin D [25(OH)D] concentration with risks of death due to cardiovascular disease, cancer, and non-vascular/non-cancer causes [10]. Suggested biological functions in the suspected causal pathway include immune-modulatory properties, induction of cell differentiation, inhibition of angiogenesis and cell proliferation, stimulation of insulin production, and inhibition of rennin production [11,12,7,13-15]. Given the high prevalence of vitamin D deficiency worldwide, this issue is becoming of paramount importance [16]. Most of the biologic activities of vitamin D are mediated by its binding to a high-affinity nuclear receptor (VDR) that acts as a ligand-activated transcription factor. A crucial step in the control of gene transcription by VDR involves heterodimerization with the retinoid X receptor (RXR), in order that high affinity binding of the heterodimer (RXR-VDR) to specific DNA sites – the vitamin D response elements (VDREs) – can occur [17]. However, excessively high concentrations of 9-cis-retinoic acid, an active metabolite of vitamin A and the ligand of RXR, can lead to the formation of RXR-RXR homodimers instead of

heterodimers with VDR. If this highly regulated heterodimerisation process is interrupted, vitamin D cannot exert its important transcriptional effects in the human body [18]. Recent data from epidemiological studies suggest that the association between 25(OH)D and cancer incidence or mortality is modified by vitamin A, such that excess circulating vitamin A may attenuate a beneficial association [19-22]. Studies on the association of 25(OH)D with mortality other than cancer mortality so far have not considered a potential vitamin D-vitamin A interaction effect. We tested the hypothesis that inverse associations of serum 25(OH)D with all-cause, cancer, CVD and non-cancer/non-CVD mortality are modified by circulating levels of vitamin A in a prospective cohort of healthy US adults (NHANES III; 1988–1994).

SUBJECTS AND METHODS

Study population

NHANES is a data collection program designed to assess the health and nutritional status of the civilian, non-institutionalized population in the United States. The third NHANES study was conducted by the National Center for Health Statistics (NCHS) between 1988 and 1994 using a stratified, multistage probability design. In order to provide reliable estimates for specific subgroups of the US population, young children, older persons (aged 65 or older), black persons, and Mexican Americans were oversampled. NHANES III collected household interview data including demographics and data on health and nutrition for 33,994 (85.6%) of the 39,695 invited participants. Subsequent physical and laboratory examinations in mobile examination centers (MEC) or at home visits were conducted for 30,882 (77.8%) subjects. The NCHS Institutional Review Board approved all procedures, and all subjects

were provided a written informed consent sheet. Detailed methods for the NHANES III baseline data collection, including sampling, in-house interview, physical examination, laboratory measurements, mortality linkage, ethics approval, and informed consent have been described elsewhere [23]. All analyses in this report are based on NHANES data extracted from the publicly available NHANES website.

Our analysis was restricted to the 20,024 adults, defined as 17 years or older in NHANES III. We excluded those who did not complete both the interview and the subsequent MEC examination including a blood draw (n=1875), women who were pregnant at baseline (n=280), individuals without reported serum 25(OH)D measurement (n=1159) and participants without complete information on the study variables (n=712), resulting in a cohort of 15,998 individuals.

Mortality follow-up

The NHANES III linked mortality file provides mortality follow-up data from the date of survey participation (1988-1994) through December 31, 2006. All participants aged 17 years or older at baseline were eligible for mortality follow-up. Vital status was assessed based primarily upon the results from a probabilistic match between NHANES III and National Death Index (NDI) death certificate records [24]. The follow-up period was calculated as the time from examination to either a mortal event or censoring date. Underlying cause of death was coded using the 9th revision of the International Statistical Classification of Diseases, Injuries, and Causes of Death (ICD-9) for deaths occurring between 1988 and 1998, and the 10th ICD revision (ICD-10) for deaths occurring between 1999 and 2006. All death before 1999 were recoded by the NCHS to ICD-10 codes for

comparability. Cardiovascular disease mortality was defined as ICD-10 codes I00–I99, corresponding to the ICD-9 codes 390–434 and 436–459 and cancer mortality as ICD-10 codes C00–C34, C37–C41, C43–C49, C50–C52, C54–C65, C67–C80, C82–C85, C88, C90–C95 and C97, corresponding to the ICD-9 codes 140–239. Non-cancer/non-CVD mortality included all death with known underlying causes, except CVD and cancer deaths. All-cause mortality included all specified causes of death as well as cases with unknown cause. During the median 14.5 years of follow-up, there were 3890 (24%) deaths in our analytical cohort, including 1715 CVD-related deaths and 844 cancer-related deaths.

Covariate assessment

Information on age, sex, race/ethnicity, and socioeconomic status was obtained by self-report from the household interview. Race/ethnicity was reported as non-Hispanic white, non-Hispanic black, Mexican-American (defined as persons of Mexican origin living in the United States), and others (including multiracial). Age was defined as the age in years at time of recruitment. Socioeconomic status was assessed using the poverty income ratio, a calculated variable based on family income and family size, and self-reported years of schooling (less, equal, more than high school). Information on alcohol consumption was divided into 3 categories (none, 1–8, 9+ times/month) and smoking history was classified according to current (1-20 cigarettes/day, >20 cigarettes/day), former or never smokers. The level of physical activity was categorized into none, 1-3, 4+ times of moderate physical activity per week. In women, hormone replacement therapy was also assessed. History of obstructive pulmonary disease (defined as any positive response to one of the diagnoses of asthma, emphysema or chronic bronchitis), as well as myocardial infarction, stroke, heart

failure, and cancer were assessed through self-reporting. Intake and type (product label) of mineral and vitamin supplements were recorded from the 30-day supplement interview. As there is no evidence that pro-vitamin A properties arising from dietary intakes of carotenoids contribute to vitamin A-related toxicity [25,26], the present study only considered intake of supplements containing preformed vitamin A in the form of retinol and its esters. Supplement use was divided into quartiles based on information on frequency and quantity (units each time) of consumption in the past month.

From physical examination data, height and weight were used to calculate the body mass index (BMI) as kg/m^2. Hypertension, diabetes mellitus and hypercholesterolemia were defined by history/physician's diagnosis or medication use. Fasting blood samples collected during examination were centrifuged, aliquoted, and frozen to -70°C before transport on dry ice to central laboratories for analysis. Blood collection in mobile unites was performed in two seasonal groups based generally on latitude, with southern collections undertaken during the winter months (November to March), and northern collections during the summer months (April to October). To account for variability of latitude and season, we divided our sample into two groups: winter/ lower latitude and summer/higher latitude. Serum 25(OH)D was measured using a radio-immunoassay kit (Diasorin, Stillwater, MN). Serum levels of retinol and retinyl esters (that is, the sum of retinyl linoleate, retinyl oleate, retinyl palmitate and retinyl stearate) were assayed by isocratic high-performance liquid chromatography with detection at three different wavelengths (Waters, Milford, MA).

Statistical Analysis

All analyses were performed using STATA statistical software version 13 (StataCorp. 2013, College Station, Texas, USA). In order to account for the complex survey design of NHANES III all analyses were weighted by using the ‘‘survey’’ command, with the “subpop” option to subset data. A 2-sided P value of 0.05 was the criterion for statistical significance. Continuous variables are expressed as mean +/- standard deviation (SD), categorical variables are presented as proportions. Cox proportional hazard regression models were used to examine the association between 25(OH)D concentrations and mortality, whereby multivariable–adjusted hazard ratios (HR) and 95 % confidence intervals (CI) were estimated for total and cause-specific mortality. Serum 25(OH)D concentration was modeled continuously (per 10 ng/mL) and in quartiles based on the unweighted distribution in the cohort. For all participants, time at entry was the date of physical examination. Time at exit was either date of death or date of censoring, whichever came first. Covariates included in the multivariable models were selected a priori. The primary analysis focused on the association between baseline serum 25(OH)D concentration and all-cause, cancer, CVD, and non-cancer/non-CVD mortality during follow-up. Three different multivariable models were used, specified a priori, to test for the independent effect of serum 25(OH)D on mortality. The first model adjusted for age, sex, race/ethnicity and season. Building on the first model, the second model further adjusted for lifestyle and socioeconomic factors, including BMI, smoking status, alcohol consumption, physical activity, and hormone replacement therapy in women as well as poverty income ratio and education level. The third model added potential mediators in the suspected causal pathway to help explain the observed associations. This model also included hypertension, diabetes mellitus, hypercholesterolemia, obstructive pulmonary disease, and history of

myocardial infarction, stroke, and cancer. To examine a potential modifying effect of vitamin A on main effects of serum 25(OH)D we ran stratified analyses by excess circulating vitamin A and preformed vitamin A supplement use. Currently, there is no well-accepted, non-invasive physiological measure of vitamin A excess. Serum retinol is tightly regulated by liver storage and by the production of retinol-binding protein, and is likely a better biomarker of vitamin A deficiency rather than excess [27]. While serum retinol may only slightly be elevated when vitamin A intake is excessive, serum retinyl esters are markedly increased [28]. Therefore, fasting retinyl ester levels have been used as a marker of possible vitamin A toxicity or hypervitaminosis A [29,30]. Under normal conditions retinyl esters account for less than 5% of total serum vitamin A [30] and concentrations ≥7.0 μg/dL have been interpreted as marker of potential toxicity [27]. In our study, excess circulating vitamin A was therefore defined as serum retinyl esters ≥7 μg/dL. Data were also stratified by quartiles of serum retinol and preformed vitamin A intake from supplements. Since a definitive cut-off value to indicate excess vitamin A is lacking for both markers, the 75th percentile was used as threshold in the analyses. Effect modification was assessed on a multiplicative scale by using the Wald test to compare adjusted Cox models with and without an interaction term of serum 25(OH)D and the vitamin A stratification variable. To at least partially preclude reverse causation, we conducted additional analyses by excluding cases during the first 5 years of follow-up. Restricted cubic spline models were used to provide evidence of non-linear relations between 25(OH)D and mortality.

RESULTS

Table 1 summarizes demographic characteristics and confounding variables of the weighted NHANES III sample according to serum 25(OH)D quartiles. Median 25(OH)D concentration was 28.3 ng/mL (weighted sample), mean age at baseline was 43.4 years. Individuals with low 25(OH)D concentrations were older, less physically active, and more often female. Blacks and Mexican Americans were overrepresented in the lowest quartile of 25(OH)D concentration. Higher 25(OH)D concentration was associated with a higher educational level, higher income, and lower prevalence of diabetes, hypertension, COPD, as well as history of stroke and myocardial infarction.

During the 14.5 years of follow-up, 3890 (24.3 %) of the 15,998 study participants died. Of these, 844 (21.7 %) deaths were related to cancer and 1715 (44.1 %) to CVD. A significant association of serum 25(OH)D with all-cause mortality was observed when adjusting for age, sex, race/ethnicity and season (HR: 0.89; 95% CI: 0.85, 0.94 per 10 ng/mL increase in 25(OH)D; **Table 2**). The inverse association remained statistically significant even after controlling for potential confounders and intermediate variables (HR: 0.93; 95 % CI: 0.89, 0.97 per 10 ng/mL increase in 25(OH)D). A similar pattern was observed in the categorical model, where HRs tended to decrease with increasing quartiles of 25(OH)D. Comparing individuals with a high 25(OH)D concentration of ≥40 ng/mL (100 nmol/L) to those with concentrations <16 ng/mL (25 nmol/L), we observed a HR of 0.70 (95% CI: 0.50, 0.83). Excluding the first five years of follow-up did not materially affect the observed associations (data not shown). Results of the restricted cubic spline models did not indicate a non-linear association between serum 25(OH)D and mortality (*P*-value >0.05; results not shown).

The inverse association between 25(OH)D and all-cause mortality remained statistically significant among participants with serum retinyl ester concentrations <7.0 μg/dL (HR:

0.92; 95% CI 0.88, 0.97 per 10 ng/mL increase in 25(OH)D), but not among those with serum retinyl esters ≥7.0 μg/dL (HR: 0.97, 95% CI 0.85, 1.09; *P*-interaction = 0.59). Similarly, in the categorical model a statistically significant inverse association of serum 25(OH)D with all-cause mortality was observed for serum retinyl esters <7.0 μg/dL (**Figure 1**). When data were stratified by preformed vitamin A supplement use, effect estimates were generally lower among participants taking supplements. However, looking at vitamin A supplement use in more detail, the potential protective effect of 25(OH)D on overall mortality held for individuals taking supplements containing preformed vitamin A at amounts ≤5000 IU (HR: 0.87,95% CI 0.77, 0.97 per 10 ng/mL increase in 25(OH)D), but not for those taking high amounts (>5000 IU) of preformed vitamin A from supplements (HR: 1.01, 95% CI 0.72, 1.43; *P*-interaction = 0.53). However, these results should be interpreted with caution due to the low case numbers in the subgroups. When stratifying by serum retinol, HR tended to decrease with increasing quartiles of 25(OH)D concentrations in both strata, with the risk reduction being more pronounced at high concentrations (>69 μg/dL) of serum retinol (HR: 0.64, 95% CI 0.48, 0.86 for serum retinol >69 μg/dL and HR: 0.82, 95% CI 0.71, 0.96 for serum retinol ≤ 69 μg/dL; top vs. bottom quartile; *P*-interaction = 0.16). Generally, the strength of associations was similar when analyses were stratified by sex (**Supplementary Table 1**).

Overall, there was no significant association between serum 25(OH)D and total cancer mortality (**Supplementary Table 2**). Similar to associations seen with all-cause mortality, lower 25(OH)D was associated with increased CVD mortality (HR = 0.79, 95% CI 0.67, 0.94; top vs. bottom quartile, model 3; Supplementary Table 2). At serum retinyl ester concentrations <7 μg/dL and serum retinol concentrations > 69 μg/dL, 25(OH)D

maintained its inverse association with CVD mortality (HR: 0.76, 95% CI 0.61, 0.95 and HR: 0.62, 95% CI 0.44, 0.89, respectively; top vs. bottom quartile). Mortality due to non-cancer/non-CVD causes was significantly inversely associated with 25(OH)D in the multivariable-adjusted model (HR: 0.89, 95% CI 0.82, 0.97 per 10 ng/mL increase in 25(OH)D). Lower serum retinyl esters as well as preformed vitamin A supplement use were associated with lower mortality (HR: 0.87, 95% CI 0.78, 0.96 and HR: 0.79, 95% CI 0.65,0.95, respectively, per 10 ng/mL increase in 25(OH)D). Whether differences in preformed vitamin A intake from supplements modify risk estimates for cause-specific mortality could not be assessed due to the low number of cases in the supplementation group.

DISCUSSION

In this nationally representative sample of US adults, we observed an inverse association of serum 25(OH)D with all-cause mortality, CVD mortality and mortality due to non-cancer/non-CVD causes. We found these associations to be modified by circulating concentrations of serum retinyl ester, a commonly used biomarker of possible vitamin A excess, in a way that the beneficial associations were attenuated among those with excessively high concentrations (≥7 μg/dL). In addition, high preformed vitamin A intake (>5000 IU) from supplements was found to diminish the inverse association of 25(OH)D with overall mortality. However, there was limited statistical evidence of an interaction between 25(OH)D and vitamin A exposure.

Our results on the relation of serum 25(OH)D and mortality corroborate earlier findings. A recently published patient level meta-analysis of eight observational studies from Europe

and the United States, including the NHANES III survey, has shown that low 25(OH)D is associated with an increase in all-cause and cardiovascular mortality, with a curvilinear inverse association between 25(OH)D concentration and mortality outcomes [31]. These results are similar to previous study level meta-analyses of observational studies, where vitamin D deficiency has been suggested as an independent risk factor for all-cause and CVD mortality [32-34,8,35]. While the association between serum 25(OH)D and CVD mortality appears to be a strong inverse association, findings regarding cancer mortality are heterogeneous. Most prospective studies and meta-analyses have focused on colorectal, breast, and prostate cancer and often yielded different results depending on tumour type [36-43]. Schottker et al. [31] observed an association only among subjects with a history of cancer, and two other recently published meta-analyses showed weak, albeit statistically significant, elevated pooled risk ratios [10,44]. Studies using data of NHANES III have reported an inverse association between circulating concentrations of 25(OH)D and overall [45] as well as cardiovascular disease mortality [46], but the associations with cancer mortality were not entirely clear [47]. These studies differed from our study in that the length of follow-up was shorter (7.3 years [46] and 8.7 years [45]) and one study [46] only included participants aged 65 or older.

We further observed that the inverse associations between 25(OH)D and mortality were diminished among those with excess circulating retinyl esters. The fact that this pattern did not hold for serum retinol strata does not conflict with other reports that suggest that retinol concentrations are under tight homeostatic control and may remain constant or decline to compensate for higher retinyl ester concentrations [29,48]. The large differences in risk estimates we observed between strata of vitamin A variables did mostly not result in

303 a significant vitamin D-vitamin A interaction, which may be attributed to small case
304 numbers in the respective subgroups. Previous evidence as to whether vitamin A modifies
305 vitamin D's effect on mortality is limited. To our knowledge, this is the first study to
306 examine a possible vitamin D-vitamin A interaction not only in association with cancer
307 mortality, but also with overall, CVD, and non-cancer/non-CVD mortality. Among the few
308 epidemiological studies investigating the influence of vitamin A on vitamin D-related cancer
309 risks, high intakes of retinol were found to mask a beneficial association of vitamin D with
310 colorectal and pancreatic cancer [22,21]. Several studies on lung cancer have recently been
311 published but results are conflicting. Cheng, Neuhouser [19] reported that the inverse
312 association of 25(OH)D with lung cancer mortality seen in non-smokers was more likely to
313 be observed among those with no sign of excess vitamin A exposure in NHANES III.
314 Similarly, a recent study in postmenopausal women reported suggestive evidence that
315 lower vitamin A intake may be important for a beneficial association of vitamin D
316 supplementation with lung cancer risk [20]. However, statistical evidence to support effect
317 modification by vitamin A was limited in both studies. In the Alpha-Tocopherol, Beta-
318 Carotene Cancer Prevention Study (ATBC) serum retinol was not found to modify the effect
319 of vitamin D on lung cancer risk [49] and results of the Carotene and Retinol Efficacy Trial
320 (CARET) showed that high-dose vitamin A may be important for the protective effect of
321 vitamin D against lung cancer among smokers [50]. Caution should be exercised when
322 comparing our results to these findings. In most studies the primary outcome was cancer
323 incidence rather than mortality. In addition, no study but one [19] used retinyl ester as
324 biomarker of vitamin A excess and studies on vitamin A intake usually included pro-vitamin
325 A carotenoids.

Overall, serum 25(OH)D was similarly inversely associated with all-cause and cause-specific mortality when we stratified analyses by sex. Other studies that reported their results for all-cause mortality stratified by sex have found very similar results for both sexes [51,52], stronger associations in men [53], or stronger associations in women [45]. One study reported a difference between sexes for cause-specific death [54]. Interestingly, we found the amount of supplemental preformed vitamin A intake to significantly modify the effect of vitamin D on all-cause mortality. Low case numbers among supplement users did not allow for gender-specific analyses for cause-specific mortality.

Although we cannot exclude that vitamin D interferes with vitamin A metabolism rather than the other way around, the biological mechanism by which circulating vitamin A is thought to mask a beneficial association of 25(OH)D with mortality seems plausible and has frequently been discussed in the literature [17,55,18]. It involves excessively high concentrations of 9-cis-retinoic acid, an active metabolite of vitamin A, leading to retinoid X receptor (RXR) homodimers (RXR-RXR) instead of VDR-RXR heterodimers. Serum concentrations of 9-cis-retinoic acid are directly related to dietary vitamin A intake [56], but the precise concentration of vitamin A leading to disturbance of heterodimerisation remains unknown. In most developed countries including the U.S., consumption of multivitamin or single supplement products commonly consisting of high-dose preformed vitamin A has increased over time and concerns of subclinical vitamin A toxicity have already been raised [57-59]. In our cohort, 21% of study participants took supplements containing preformed vitamin A and more than 20% had excess circulating vitamin A, defined as retinyl esters ≥7.0 μg/dL.

The strengths of our study include statistical adjustment for a wide range of factors. Furthermore, NHANES III is a large well-characterized survey, which incorporates a representative sample of the U.S. population. A number of limitations should be considered when interpreting our results. First, serum 25(OH)D was only measured once in NHANES III. Second, serum 25(OH)D data from NHANES III have an inherent season-latitude structure that prevents assessing associations in specific subgroups. In addition, results of sub-analyses should be interpreted with caution because of low number of cases. Moreover, adequate concentrations of vitamin D may reflect a pattern of behavior to minimize threats to one's health and thus be a proxy for a healthy lifestyle. Although we controlled for numerous confounders, potential residual and unmeasured confounding remains a distinct possibility.

In this study, inverse associations of 25(OH)D with overall, CVD and non-cancer/non-CVD mortality were found to be diminished if circulating vitamin A was excessively high (retinyl esters ≥7.0 μg/dL). The beneficial association between 25(OH)D and all-cause mortality further remained statistically significant only in participants taking preformed vitamin A from supplements in amounts ≤5000 IU. If the interaction effect is real, i.e. vitamin A interferes with the action of vitamin D, our findings underscore the need to assess safety of high intakes of preformed vitamin A in order to prevent toxic levels in the body that potentially undermine a protective effect of vitamin D. Other than with preformed vitamin A intake, a diet rich in red and yellow-orange fruits and vegetables such as carrots and sweet potatoes would supply all the carotenoids the body needs to make retinol without the potential for hypervitaminosis A. Further well-designed studies to more clearly identify a

potential causal relationship of vitamin D with overall and cause-specific mortality as well as a potential interaction with vitamin A are warranted.

ACKNOWLEDGEMENTS

We thank Aline Richard for her help in initial stages of statistical analysis.

The authors' responsibilities were as follows—SR and ES: designed the research, had full access to all the data, and take responsibility for the integrity of data and accuracy of data analysis; ES: conducted the data research and statistical analysis and wrote, reviewed, and edited the manuscript; all authors: reviewed, edited and approved the manuscript. None of the authors declared a conflict of interest.

Role of sponsors: No sponsors.

Competing interests: None declared.

References

1. Pilz S, Tomaschitz A, Marz W, Drechsler C, Ritz E, Zittermann A, Cavalier E, Pieber TR, Lappe JM, Grant WB, Holick MF, Dekker JM (2011) Vitamin D, cardiovascular disease and mortality. Clin Endocrinol 75 (5):575-584. doi:Doi 10.1111/J.1365-2265.2011.04147.X

2. Arnson Y, Amital H, Shoenfeld Y (2007) Vitamin D and autoimmunity: new aetiological and therapeutic considerations. Annals of the rheumatic diseases 66 (9):1137-1142. doi:10.1136/ard.2007.069831

3. Souberbielle JC, Body JJ, Lappe JM, Plebani M, Shoenfeld Y, Wang TJ, Bischoff-Ferrari HA, Cavalier E, Ebeling PR, Fardellone P, Gandini S, Gruson D, Guerin AP, Heickendorff L, Hollis BW, Ish-Shalom S, Jean G, von Landenberg P, Largura A, Olsson T, Pierrot-Deseilligny C, Pilz S, Tincani A, Valcour A, Zittermann A (2010) Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice. Autoimmunity reviews 9 (11):709-715. doi:10.1016/j.autrev.2010.06.009

4. Urashima M, Segawa T, Okazaki M, Kurihara M, Wada Y, Ida H (2010) Randomized trial of vitamin D supplementation to prevent seasonal influenza A in schoolchildren. The American journal of clinical nutrition 91 (5):1255-1260. doi:10.3945/ajcn.2009.29094

5. Sabetta JR, DePetrillo P, Cipriani RJ, Smardin J, Burns LA, Landry ML (2010) Serum 25-hydroxyvitamin d and the incidence of acute viral respiratory tract infections in healthy adults. PloS one 5 (6):e11088. doi:10.1371/journal.pone.0011088

403 6. Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ (2014) The role of vitamin
404 D in reducing cancer risk and progression. Nature reviews Cancer. doi:10.1038/nrc3691
405 7. Welsh J (2012) Cellular and molecular effects of vitamin D on carcinogenesis. Arch
406 Biochem Biophys 523 (1):107-114. doi:Doi 10.1016/J.Abb.2011.10.019
407 8. Zittermann A, Iodice S, Pilz S, Grant WB, Bagnardi V, Gandini S (2012) Vitamin D
408 deficiency and mortality risk in the general population: a meta-analysis of prospective
409 cohort studies. The American journal of clinical nutrition 95 (1):91-100.
410 doi:10.3945/ajcn.111.014779
411 9. Holick MF (2007) Vitamin D deficiency. The New England journal of medicine 357
412 (3):266-281. doi:10.1056/NEJMra070553
413 10. Chowdhury R, Kunutsor S, Vitezova A, Oliver-Williams C, Chowdhury S, Kiefte-de-Jong
414 JC, Khan H, Baena CP, Prabhakaran D, Hoshen MB, Feldman BS, Pan A, Johnson L, Crowe F,
415 Hu FB, Franco OH (2014) Vitamin D and risk of cause specific death: systematic review and
416 meta-analysis of observational cohort and randomised intervention studies. Bmj
417 348:g1903. doi:10.1136/bmj.g1903
418 11. Prietl B, Treiber G, Pieber TR, Amrein K (2013) Vitamin D and Immune Function.
419 Nutrients 5 (7):2502-2521. doi:Doi 10.3390/Nu5072502
420 12. Hewison M (2012) An update on vitamin D and human immunity. Clin Endocrinol (Oxf)
421 76 (3):315-325. doi:10.1111/j.1365-2265.2011.04261.x
422 13. Bikle D (2009) Nonclassic actions of vitamin D. The Journal of clinical endocrinology and
423 metabolism 94 (1):26-34. doi:10.1210/jc.2008-1454
424 14. Lee S, Clark SA, Gill RK, Christakos S (1994) 1,25-Dihydroxyvitamin D3 and pancreatic
425 beta-cell function: vitamin D receptors, gene expression, and insulin secretion.
426 Endocrinology 134 (4):1602-1610. doi:10.1210/endo.134.4.8137721
427 15. Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP (2002) 1,25-Dihydroxyvitamin D(3) is a
428 negative endocrine regulator of the renin-angiotensin system. The Journal of clinical
429 investigation 110 (2):229-238. doi:10.1172/JCI15219
430 16. Mithal A, Wahl DA, Bonjour JP, Burckhardt P, Dawson-Hughes B, Eisman JA, El-Hajj
431 Fuleihan G, Josse RG, Lips P, Morales-Torres J, Group IOFCoSANW (2009) Global vitamin D
432 status and determinants of hypovitaminosis D. Osteoporosis international : a journal
433 established as result of cooperation between the European Foundation for Osteoporosis
434 and the National Osteoporosis Foundation of the USA 20 (11):1807-1820.
435 doi:10.1007/s00198-009-0954-6
436 17. Haussler MR, Haussler CA, Jurutka PW, Thompson PD, Hsieh JC, Remus LS, Selznick SH,
437 Whitfield GK (1997) The vitamin D hormone and its nuclear receptor: molecular actions
438 and disease states. The Journal of endocrinology 154 Suppl:S57-73
439 18. Thompson PD, Jurutka PW, Haussler CA, Whitfield GK, Haussler MR (1998)
440 Heterodimeric DNA binding by the vitamin D receptor and retinoid X receptors is enhanced
441 by 1,25-dihydroxyvitamin D3 and inhibited by 9-cis-retinoic acid. Evidence for allosteric
442 receptor interactions. The Journal of biological chemistry 273 (14):8483-8491
443 19. Cheng TY, Neuhouser ML (2012) Serum 25-hydroxyvitamin D, vitamin A, and lung
444 cancer mortality in the US population: a potential nutrient-nutrient interaction. Cancer
445 causes & control : CCC 23 (9):1557-1565. doi:10.1007/s10552-012-0033-8
446 20. Cheng TY, Lacroix AZ, Beresford SA, Goodman GE, Thornquist MD, Zheng Y, Chlebowski
447 RT, Ho GY, Neuhouser ML (2013) Vitamin D intake and lung cancer risk in the Women's

448 Health Initiative. The American journal of clinical nutrition 98 (4):1002-1011.
449 doi:10.3945/ajcn.112.055905
450 21. Oh K, Willett WC, Wu K, Fuchs CS, Giovannucci EL (2007) Calcium and vitamin D intakes
451 in relation to risk of distal colorectal adenoma in women. American journal of epidemiology
452 165 (10):1178-1186. doi:10.1093/aje/kwm026
453 22. Bao Y, Ng K, Wolpin BM, Michaud DS, Giovannucci E, Fuchs CS (2010) Predicted vitamin
454 D status and pancreatic cancer risk in two prospective cohort studies. British journal of
455 cancer 102 (9):1422-1427. doi:10.1038/sj.bjc.6605658
456 23. National Center for Health Statistics (1994) Plan and operation of the third National
457 Health and Nutrition Examination Survey, 1988-94. vol 32. Natl Ctr for Health Statistics,
458 24. Dukas L, Platz EA, Colditz GA, Willet WC, Giovannucci EL (2000) Bowel movement, use
459 of laxatives and risk of colorectal adenomatous polyps among women (United States).
460 Cancer Causes Control 11 (10):907-914
461 25. European Commission, Scientific Committee on Food (2002) Opinion of the Scientific
462 Committee on Food on the Tolerable Upper Intake Level of Preformed Vitamin A (retinol
463 and retinyl esters).
464 26. Blomhoff R, Beckman-Sundh U, Brot C, Solvoll C, Steingrimsdóttir L, Carlsen MH (2003)
465 Health risks related to high intake of preformed retinol (vitamin A) in the Nordic countries.
466 Nordic Council of Ministers
467 27. Ballew C, Galuska D, Gillespie C (2001) High serum retinyl esters are not associated with
468 reduced bone mineral density in the Third National Health And Nutrition Examination
469 Survey, 1988-1994. Journal of bone and mineral research : the official journal of the
470 American Society for Bone and Mineral Research 16 (12):2306-2312.
471 doi:10.1359/jbmr.2001.16.12.2306
472 28. Willett W (2013) Nutritional epidemiology, vol vol. 40. Oxford University Press, Oxford
473 29. Krasinski SD, Russell RM, Otradovec CL, Sadowski JA, Hartz SC, Jacob RA, McGandy RB
474 (1989) Relationship of vitamin A and vitamin E intake to fasting plasma retinol, retinol-
475 binding protein, retinyl esters, carotene, alpha-tocopherol, and cholesterol among elderly
476 people and young adults: increased plasma retinyl esters among vitamin A-supplement
477 users. The American journal of clinical nutrition 49 (1):112-120
478 30. Smith FR, Goodman DS (1976) Vitamin A transport in human vitamin A toxicity. The
479 New England journal of medicine 294 (15):805-808. doi:10.1056/NEJM197604082941503
480 31. Schottker B, Jorde R, Peasey A, Thorand B, Jansen EH, Groot L, Streppel M, Gardiner J,
481 Ordonez-Mena JM, Perna L, Wilsgaard T, Rathmann W, Feskens E, Kampman E, Siganos G,
482 Njolstad I, Mathiesen EB, Kubinova R, Pajak A, Topor-Madry R, Tamosiunas A, Hughes M,
483 Kee F, Bobak M, Trichopoulou A, Boffetta P, Brenner H, Consortium on H, Ageing: Network
484 of Cohorts in E, the United S (2014) Vitamin D and mortality: meta-analysis of individual
485 participant data from a large consortium of cohort studies from Europe and the United
486 States. Bmj 348:g3656. doi:10.1136/bmj.g3656
487 32. Bjelakovic G, Gluud LL, Nikolova D, Whitfield K, Wetterslev J, Simonetti RG, Bjelakovic M,
488 Gluud C (2014) Vitamin D supplementation for prevention of mortality in adults. The
489 Cochrane database of systematic reviews 1:CD007470.
490 doi:10.1002/14651858.CD007470.pub3
491 33. Rush L, McCartney G, Walsh D, Mackay D (2013) Vitamin D and subsequent all-age and
492 premature mortality: a systematic review. BMC public health 13 (1):679.
493 doi:10.1186/1471-2458-13-679

494 34. Schottker B, Ball D, Gellert C, Brenner H (2013) Serum 25-hydroxyvitamin D levels and
495 overall mortality. A systematic review and meta-analysis of prospective cohort studies.
496 Ageing research reviews 12 (2):708-718. doi:10.1016/j.arr.2012.02.004
497 35. Wang L, Song Y, Manson JE, Pilz S, Marz W, Michaelsson K, Lundqvist A, Jassal SK,
498 Barrett-Connor E, Zhang C, Eaton CB, May HT, Anderson JL, Sesso HD (2012) Circulating 25-
499 hydroxy-vitamin D and risk of cardiovascular disease: a meta-analysis of prospective
500 studies. Circulation Cardiovascular quality and outcomes 5 (6):819-829.
501 doi:10.1161/CIRCOUTCOMES.112.967604
502 36. Pilz S, Tomaschitz A, Obermayer-Pietsch B, Dobnig H, Pieber TR (2009) Epidemiology of
503 vitamin D insufficiency and cancer mortality. Anticancer research 29 (9):3699-3704
504 37. Bikle DD (2014) Vitamin D and cancer: the promise not yet fulfilled. Endocrine 46
505 (1):29-38. doi:10.1007/s12020-013-0146-1
506 38. Michaelsson K, Baron JA, Snellman G, Gedeborg R, Byberg L, Sundstrom J, Berglund L,
507 Arnlov J, Hellman P, Blomhoff R, Wolk A, Garmo H, Holmberg L, Melhus H (2010) Plasma
508 vitamin D and mortality in older men: a community-based prospective cohort study. The
509 American journal of clinical nutrition 92 (4):841-848. doi:10.3945/ajcn.2010.29749
510 39. Chen P, Hu P, Xie D, Qin Y, Wang F, Wang H (2010) Meta-analysis of vitamin D, calcium
511 and the prevention of breast cancer. Breast cancer research and treatment 121 (2):469-
512 477. doi:10.1007/s10549-009-0593-9
513 40. Gandini S, Boniol M, Haukka J, Byrnes G, Cox B, Sneyd MJ, Mullie P, Autier P (2011) Meta-
514 analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal,
515 breast and prostate cancer and colorectal adenoma. International journal of cancer Journal
516 international du cancer 128 (6):1414-1424. doi:10.1002/ijc.25439
517 41. Gilbert R, Martin RM, Beynon R, Harris R, Savovic J, Zuccolo L, Bekkering GE, Fraser WD,
518 Sterne JA, Metcalfe C (2011) Associations of circulating and dietary vitamin D with prostate
519 cancer risk: a systematic review and dose-response meta-analysis. Cancer causes & control :
520 CCC 22 (3):319-340. doi:10.1007/s10552-010-9706-3
521 42. Ma Y, Zhang P, Wang F, Yang J, Liu Z, Qin H (2011) Association between vitamin D and
522 risk of colorectal cancer: a systematic review of prospective studies. Journal of clinical
523 oncology : official journal of the American Society of Clinical Oncology 29 (28):3775-3782.
524 doi:10.1200/JCO.2011.35.7566
525 43. Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H (2011) Meta-analysis: Serum
526 vitamin D and colorectal adenoma risk. Preventive medicine 53 (1-2):10-16.
527 doi:10.1016/j.ypmed.2011.05.013
528 44. Yin L, Ordonez-Mena JM, Chen T, Schottker B, Arndt V, Brenner H (2013) Circulating 25-
529 hydroxyvitamin D serum concentration and total cancer incidence and mortality: a
530 systematic review and meta-analysis. Preventive medicine 57 (6):753-764.
531 doi:10.1016/j.ypmed.2013.08.026
532 45. Melamed ML, Michos ED, Post W, Astor B (2008) 25-hydroxyvitamin D levels and the
533 risk of mortality in the general population. Archives of internal medicine 168 (15):1629-
534 1637. doi:10.1001/archinte.168.15.1629
535 46. Ginde AA, Scragg R, Schwartz RS, Camargo CA, Jr. (2009) Prospective study of serum 25-
536 hydroxyvitamin D level, cardiovascular disease mortality, and all-cause mortality in older
537 U.S. adults. Journal of the American Geriatrics Society 57 (9):1595-1603.
538 doi:10.1111/j.1532-5415.2009.02359.x

539 47. Freedman DM, Looker AC, Abnet CC, Linet MS, Graubard BI (2010) Serum 25-
540 hydroxyvitamin D and cancer mortality in the NHANES III study (1988-2006). Cancer
541 research 70 (21):8587-8597. doi:10.1158/0008-5472.CAN-10-1420
542 48. Ragavan VV, Smith JE, Bilezikian JP (1982) Vitamin A toxicity and hypercalcemia. The
543 American journal of the medical sciences 283 (3):161-164
544 49. Weinstein SJ, Yu K, Horst RL, Parisi D, Virtamo J, Albanes D (2011) Serum 25-
545 hydroxyvitamin D and risk of lung cancer in male smokers: a nested case-control study.
546 PloS one 6 (6):e20796. doi:10.1371/journal.pone.0020796
547 50. Cheng TY, Goodman GE, Thornquist MD, Barnett MJ, Beresford SA, Lacroix AZ, Zheng Y,
548 Neuhouser ML (2014) Estimated intake of vitamin D and its interaction with vitamin A on
549 lung cancer risk among smokers. International journal of cancer Journal international du
550 cancer. doi:10.1002/ijc.28846
551 51. Bates CJ, Hamer M, Mishra GD (2012) A study of relationships between bone-related
552 vitamins and minerals, related risk markers, and subsequent mortality in older British
553 people: the National Diet and Nutrition Survey of People Aged 65 Years and Over.
554 Osteoporosis international : a journal established as result of cooperation between the
555 European Foundation for Osteoporosis and the National Osteoporosis Foundation of the
556 USA 23 (2):457-466. doi:10.1007/s00198-011-1543-z
557 52. Kestenbaum B, Katz R, de Boer I, Hoofnagle A, Sarnak MJ, Shlipak MG, Jenny NS,
558 Siscovick DS (2011) Vitamin D, parathyroid hormone, and cardiovascular events among
559 older adults. Journal of the American College of Cardiology 58 (14):1433-1441.
560 doi:10.1016/j.jacc.2011.03.069
561 53. Hutchinson MS, Grimnes G, Joakimsen RM, Figenschau Y, Jorde R (2010) Low serum 25-
562 hydroxyvitamin D levels are associated with increased all-cause mortality risk in a general
563 population: the Tromso study. European journal of endocrinology / European Federation of
564 Endocrine Societies 162 (5):935-942. doi:10.1530/EJE-09-1041
565 54. Rohrmann S, Braun J, Bopp M, Faeh D, Swiss National C (2013) Inverse association
566 between circulating vitamin D and mortality-dependent on sex and cause of death?
567 Nutrition, metabolism, and cardiovascular diseases : NMCD 23 (10):960-966.
568 doi:10.1016/j.numecd.2013.05.005
569 55. Zou A, Elgort MG, Allegretto EA (1997) Retinoid X receptor (RXR) ligands activate the
570 human 25-hydroxyvitamin D3-24-hydroxylase promoter via RXR heterodimer binding to
571 two vitamin D-responsive elements and elicit additive effects with 1,25-dihydroxyvitamin
572 D3. The Journal of biological chemistry 272 (30):19027-19034
573 56. Arnhold T, Tzimas G, Wittfoht W, Plonait S, Nau H (1996) Identification of 9-cis-retinoic
574 acid, 9,13-di-cis-retinoic acid, and 14-hydroxy-4,14-retro-retinol in human plasma after
575 liver consumption. Life sciences 59 (12):PL169-177
576 57. Millen AE, Dodd KW, Subar AF (2004) Use of vitamin, mineral, nonvitamin, and
577 nonmineral supplements in the United States: The 1987, 1992, and 2000 National Health
578 Interview Survey results. Journal of the American Dietetic Association 104 (6):942-950.
579 doi:10.1016/j.jada.2004.03.022
580 58. Bailey RL, Gahche JJ, Lentino CV, Dwyer JT, Engel JS, Thomas PR, Betz JM, Sempos CT,
581 Picciano MF (2011) Dietary supplement use in the United States, 2003-2006. The Journal of
582 nutrition 141 (2):261-266. doi:10.3945/jn.110.133025
583 59. Park YK, Kim I, Yetley EA (1991) Characteristics of vitamin and mineral supplement
584 products in the United States. The American journal of clinical nutrition 54 (4):750-759
585

TABLE 1

Baseline demographic and health-related characteristics of study participants by quartiles of serum 25-hydroxyvitamin D (25(OH)D)

	Total	25(OH)D quartiles			
		Quartile 1	Quartile 2	Quartile 3	Quartile 4
Vitamin D (ng/mL)		<17.7	17.7-24.2	24.3-32.0	>32.0
Vitamin D (nmol/L)		<44.2	44.2-60.4	60.5-79.9	>79.9
n	15998	4024	3984	3994	3996
Follow-up time (y, median)	14.5	14.3	14.5	14.7	14.4
Age (y)	43.4±16.5[1]	45.0±21.2	45.8±18.5	44.1±16.0	40.9±13.0
Female (%)	51.2	66.5	56.5	49.6	43.1
Race/ethnicity (%)					
Non-Hispanic white	76.5	46.5	67.4	81.2	90.4
Non-Hispanic black	10.6	33.8	14.3	6.1	2.3
Mexican American	5.1	7.3	7.0	5.4	2.8
Other	7.9	12.4	11.4	7.3	4.4
Season of blood collection (%)					
Winter/lower latitude	31.5	45.9	35.3	30.3	24.3
Summer/higher latitude	68.5	54.1	64.7	69.7	75.7
Body mass index (kg/m^2)	26.4±5.3	27.9±8.0	27.5±6.3	26.3±4.8	25.2±3.6
Moderate physical activity per week (%)					
≤3	39.1	40.6	43.1	39.9	35.7
>3	46.5	32.8	39.1	46.6	56.1
Never	14.4	26.6	17.8	13.5	8.2
Poverty-income ratio (%)					
Poor	17.5	25.1	19.6	16.4	14.0
Middle income	42.7	41.9	43.4	40.7	44.2
Higher income	33.5	26.6	30.2	36.7	35.8
Missing	6.3	6.4	6.9	6.2	6.0
Education (%)					
Less than high school	26.4	29.3	28.2	27.0	23.9
High school	33.5	37.2	33.8	31.1	33.5
More than high school	40.1	33.4	38.0	41.9	42.7
Smoking status (%)					
Current, ≤20 cigarettes/day	19.9	25.3	19.5	18.0	19.2
Current, >20 cigarettes/day	7.3	6.0	6.2	7.2	8.5

Former	25.3	20.5	24.2	25.8	27.5
Never	47.5	48.1	50.0	49.1	44.8
Alcohol consumption per week (%)					
≤2	26.3	25.4	25.6	26.7	26.8
>2	28.6	21.7	23.7	30.8	32.5
Never	45.1	52.9	50.6	42.6	40.7
Diabetes mellitus (%)	5.2	8.5	6.3	5.5	3.0
Hypertension (%)	18.7	23.1	21.3	18.5	15.6
Hypercholesterolemia (%)	19.5	19.0	20.9	19.1	19.1
Chronic obstructive pulmonary disease (%)	13.0	16.2	13.3	13.1	11.4
History of cancer (%)	3.5	3.1	4.0	3.7	3.3
History of stroke (%)	1.9	2.8	2.3	1.6	1.5
Histry of myocardial infarction (%)	3.3	3.9	4.0	3.2	2.8

[1]Mean±SD (all such variables)

All estimates were weighted to account for the complex survey design of NHANES III

TABLE 2

Hazard ratios with 95% confidence intervals for all-cause and cause-specific mortality in NHANES III (1988–2006)[1]

Continuous model[2]	All-cause	Cancer	CVD	Non-cancer-non-CVD
n_{cases}	3890	871	1715	1284
Model 1	0.89 (0.85,0.94)	0.98 (0.87,1.09)	0.87 (0.81,0.93)	0.87 (0.79,0.95)
Model 2	0.93 (0.88,0.97)	1.01 (0.90,1.13)	0.91 (0.85,0.98)	0.88 (0.81,0.97)
Model 3	0.93 (0.89,0.97)	1.01 (0.90,1.13)	0.92 (0.86,0.98)	0.89 (0.82,0.97)
Serum retinyl esters				
n_{cases}	963	175	413	312
≥7.0 μg/dL	0.97 (0.85,1.09)	0.94 (0.73,1.21)	0.98 (0.86,1.10)	0.98 (0.83,1.16)
n_{cases}	2927	669	1249	972
<7.0 μg/dL	0.92 (0.88,0.97)	1.04 (0.93, 1.17)	0.90 (0.82,0.98)	0.87 (0.78,0.96)
Serum retinol				
n_{cases}	1269	240	609	413
Above 75th percentile (> 69 μg/dL)	0.89 (0.82,0.96)	0.94 (0.75,1.16)	0.88 (0.78,0.99)	0.86 (0.75,0.98)
n_{cases}	2621	604	1106	871
At or below 75th percentile (≤ 69 μg/dL)	0.95 (0.90,1.01)	1.05 (0.89,1.24)	0.94 (0.86,1.03)	0.90 (0.81,0.99)
Preformed vitamin A supplement use				
n_{cases}	838	187	363	281
Yes	0.89 (0.79,1.00)	0.93 (0.71,1.21)	0.97 (0.84,1.11)	0.79 (0.65,0.95)
n_{cases}	3052	657	1352	1003
No	0.95 (0.89,1.01)	1.04 (0.90,1.19)	0.91 (0.83,0.99)	0.93 (0.84,1.04)
Preformed vitamin A intake from supplements				
n_{cases}	81			
Above 75th percentile (> 5000IU)	1.01 (0.72,1.43)			
n_{cases}	757			
At or below 75th percentile (≤ 5000IU)	0.87 (0.77,0.97)			

[1] n_{cases}, number of deaths; Model 1 was adjusted for age, sex, race/ethnicity, and season; Model 2 was adjusted for variables of model 1 and for lifestyle and socioeconomic factors (poverty-income ratio, body mass index, physical activity, smoking status, alcohol consumption, education and hormone replacement therapy); Model 3 was adjusted for variables of model 2 and for potential intermediates (hypertension, diabetes mellitus, hypercholesterolemia, history of myocardial infarction, history of stroke, and history of cancer; All P-values for interaction were >0.05

[2] Per 10 ng/mL increase in 25(OH)D entered as a continuous variable

All estimates were weighted to account for the complex survey design of NHANES III

SUPPLEMENTARY TABLE 1

Sex-specific hazard ratios with 95% confidence intervals for all-cause mortality by quartiles of serum 25-hydroxyvitamin D [25(OH)D] in NHANES III (1988–2006)[1]

	Hazard ratios (95% CI) by quartiles of 25(OH)D (ng/mL)					
	Quartile 1 (<17.7)	Quartile 2 (17.7-24.2)	Quartile 3 (24.3-32.0)	Quartile 4 (>32.0)	continuous model[2]	*P*-interaction
Men						
n_{cases}	408	514	578	602		
Model 1	1.00 (reference)	0.83 (0.68,1.01)	0.73 (0.58,0.92)	0.75 (0.61,0.93)	0.95 (0.89, 1.02)	
Model 2	1.00 (reference)	0.88 (0.73,1.07)	0.80 (0.65,1.00)	0.78 (0.64,0.95)	0.95 (0.89,1.01)	
Model 3	1.00 (reference)	0.89 (0.73,1.08)	0.79 (0.64,0.97)	0.81 (0.67,0.98)	0.95 (0.89,1.01)	
Serum retinyl esters						p_{cat}=0.71, p_{cont}=0.19
n_{cases}	51	102	128	163		
≥7.0 µg/dL	1.00 (reference)	0.92 (0.51,1.65)	0.86 (0.45,1.68)	0.94 (0.50,1.78)	1.05 (0.89,1.23)	
n_{cases}	357	412	450	439		
<7.0 µg/dL	1.00 (reference)	0.90 (0.71,1.13)	0.76 (0.59,1.00)	0.78 (0.63,0.95)	0.93 (0.87,0.99)	
Serum retinol						p_{cat}=0.29, p_{cont}=0.29
n_{cases}	101	171	199	248		
Above 75th percentile (> 69 µg/dL)	1.00 (reference)	0.66 (0.43,1.02)	0.62 (0.41,0.95)	0.60 (0.38,0.95)	0.91 (0.81,1.02)	
n_{cases}	307	343	379	354		
At or below 75th percentile (≤ 69 µg/dL)	1.00 (reference)	1.01 (0.83,1.21)	0.83 (0.66,1.05)	0.89 (0.72,1.11)	0.98 (0.90,1.06)	
Preformed vitamin A supplement use						p_{cat}=0.21, p_{cont}=0.16
n_{cases}	39	89	116	154		
Yes	1.00 (reference)	0.75 (0.47,1.22)	0.56 (0.33,0.95)	0.57 (0.35,0.94)	0.85 (0.72,1.00)	
n_{cases}	369	425	462	448		
No	1.00 (reference)	0.90 (0.73,1.10)	0.87 (0.71,1.06)	0.85 (0.70,1.03)	0.98 (0.91,1.05)	
Preformed vitamin A intake from supplements						p_{cat}=0.04, p_{cont}=0.06
n_{cases}	3	11	10	20		
Above 75th percentile (> 5000IU)	1.00 (reference)	3.10 (0.34,28.51)	1.15 (0.15,8.67)	4.93 (0.80,30.40)	1.64 (0.89,3.01)	
n_{cases}	36	78	106	134		
At or below 75th percentile (≤ 5000IU)	1.00 (reference)	0.64 (0.40,1.03)	0.48 (0.27,0.84)	0.47 (0.29,0.76)	0.80 (0.70,0.92)	
Women						
n_{cases}	582	478	411	317		
Model 1	1.00 (reference)	0.75 (0.64,0.87)	0.67 (0.55,0.81)	0.58 (0.48,0.71)	0.84 (0.77,0.91)	
Model 2	1.00 (reference)	0.84 (0.73,0.96)	0.81 (0.68,0.97)	0.73 (0.60,0.88)	0.91 (0.85,0.99)	
Model 3	1.00 (reference)	0.88 (0.77,1.01)	0.82 (0.69,0.97)	0.77 (0.63,0.95)	0.92 (0.86,1.00)	
Serum retinyl esters						p_{cat}=0.91, p_{cont}=0.64

n_{cases}	98	161	133	127		
≥7.0 μg/dL	1.00 (reference)	0.80 (0.52,1.21)	0.71 (0.47,1.07)	0.72 (0.42,1.25)	0.92 (0.76,1.12)	
n_{cases}	484	317	278	190		
<7.0 μg/dL	1.00 (reference)	0.88 (0.74,1.04)	0.82 (0.65,1.03)	0.80 (0.59,1.07)	0.93 (0.84,1.02)	
Serum retinol						p_{cat}=0.10, p_{cont}=0.38
n_{cases}	136	144	129	141		
Above 75th percentile (> 69 μg/dL)	1.00 (reference)	0.95 (0.69,1.31)	0.69 (0.50,0.95)	0.67 (0.45,1.00)	0.87 (0.76,1.00)	
n_{cases}	446	334	282	176		
At or below 75th percentile (≤ 69 μg/dL)	1.00 (reference)	0.84 (0.69,1.02)	0.88 (0.72,1.09)	0.78 (0.60,1.03)	0.93 (0.84,1.02)	
Preformed vitamin A supplement use						p_{cat}=0.14, p_{cont}=0.97
n_{cases}	72	111	125	132		
Yes	1.00 (reference)	0.76 (0.46,1.25)	0.59 (0.41,0.85)	0.66 (0.40,1.09)	0.93 (0.76,1.13)	
n_{cases}	510	367	286	185		
No	1.00 (reference)	0.91 (0.77,1.08)	0.90 (0.72,1.14)	0.77 (0.60,0.99)	0.92 (0.83,1.02)	
Preformed vitamin A intake from supplements						p_{cat}=0.50, p_{cont}=0.16
n_{cases}	3	6	6	22		
Above 75th percentile (> 5000IU)	1.00 (reference)	0.26 (0.05,1.41)	0.08 (0.00,5.15)	0.69 (0.19,2.57)	0.80 (0.49,1.31)	
n_{cases}	69	105	119	110		
At or below 75th percentile (≤ 5000IU)	1.00 (reference)	0.75 (0.46,1.21)	0.63 (0.43,0.92)	0.68 (0.43,1.09)	0.95 (0.77,1.16)	

[1] n_{cases}, number of deaths; p_{cat}, P-value of test for interaction in the categorical model; p_{cont}, P-value of test for interaction in the continuous model; Model 1 was adjusted for age, sex, race/ethnicity, and season; Model 2 was adjusted for variables of model 1 and for lifestyle and socioeconomic factors (poverty-income ratio, body mass index, physical activity, smoking status, alcohol consumption, education and hormone replacement therapy); Model 3 was adjusted for variables of model 2 and for potential intermediates (hypertension, diabetes mellitus, hypercholesterolemia, history of myocardial infarction, history of stroke, and history of cancer

[2] Per 10 ng/mL increase in 25(OH)D entered as a continuous variable

All estimates were weighted to account for the complex survey design of NHANES III

SUPPLEMENTARY TABLE 2

Hazard ratios with 95% confidence intervals for all-cause and cause-specific mortality by quartiles of serum 25-hydroxyvitamin D [25(OH)D] in NHANES III (1988–2006)[1]

	Hazard ratios (95% CI) by quartiles of 25(OH)D (ng/mL)				
	Quartile 1 (<17.7)	Quartile 2 (17.7-24.2)	Quartile 3 (24.3-32.0)	Quartile 4 (>32.0)	continuous model[2]
All-cause					
n_{cases}	990	992	989	919	
Model 1	1.00 (reference)	0.78 (0.68,0.88)	0.68 (0.59,0.79)	0.66 (0.58,0.75)	0.89 (0.85,0.94)
Model 2	1.00 (reference)	0.84 (0.75,0.94)	0.78 (0.69,0.89)	0.74 (0.65,0.83)	0.93 (0.88,0.97)
Model 3	1.00 (reference)	0.87 (0.77,0.97)	0.78 (0.69,0.89)	0.77 (0.68,0.87)	0.93 (0.89,0.97)
Serum retinyl esters					
n_{cases}	149	263	261	290	
≥7.0 µg/dL	1.00 (reference)	0.85 (0.59,1.23)	0.75 (0.52,1.10)	0.79 (0.53,1.20)	0.97 (0.85,1.09)
n_{cases}	841	729	728	629	
<7.0 µg/dL	1.00 (reference)	0.87 (0.77,1.00)	0.78 (0.65,0.92)	0.77 (0.67,0.88)	0.92 (0.88,0.97)
Serum retinol					
n_{cases}	237	315	328	389	
Above 75th percentile (> 69 µg/dL)	1.00 (reference)	0.82 (0.64,1.06)	0.66 (0.52,0.84)	0.64 (0.48,0.86)	0.89 (0.82,0.96)
n_{cases}	753	677	661	530	
At or below 75th percentile (≤ 69 µg/dL)	1.00 (reference)	0.88 (0.77,1.00)	0.82 (0.71,0.94)	0.82 (0.71,0.96)	0.95 (0.90,1.01)
Preformed vitamin A supplement use					
n_{cases}	111	200	241	286	
Yes	1.00 (reference)	0.76 (0.52,1.12)	0.58 (0.42,0.81)	0.63 (0.43,0.92)	0.89 (0.79,1.00)
n_{cases}	879	792	748	633	
No	1.00 (reference)	0.89 (0.79,1.00)	0.86 (0.74,1.00)	0.80 (0.68,0.94)	0.95 (0.89,1.01)
Preformed vitamin A intake from supplements					
n_{cases}	6	17	16	42	
Above 75th percentile (> 5000IU)	1.00 (reference)	0.86 (0.27,2.75)	0.44 (0.11,1.73)	1.13 (0.48,2.68)	1.01 (0.72,1.43)
n_{cases}	105	183	225	244	
At or below 75th percentile (≤ 5000IU)	1.00 (reference)	0.73 (0.51,1.04)	0.57 (0.41,0.80)	0.59 (0.41,0.85)	0.87 (0.77,0.97)
Cancer					
n_{cases}	201	218	214	211	
Model 1	1.00 (reference)	0.91 (0.69,1.20)	0.83 (0.63,1.10)	0.80 (0.61,1.05)	0.98 (0.87,1.09)
Model 2	1.00 (reference)	1.00 (0.75,1.32)	0.98 (0.73,1.32)	0.92 (0.67,1.25)	1.01 (0.90,1.13)
Model 3	1.00 (reference)	0.99 (0.74,1.32)	0.93 (0.68,1.27)	0.92 (0.66,1.28)	1.01 (0.90,1.13)
Serum retinyl esters					

n_{cases}	22	46	52	55	
≥7.0 μg/dL	1.00 (reference)	0.81 (0.36,1.86)	0.80 (0.33,1.97)	0.65 (0.25,1.67)	0.94 (0.73,1.21)
n_{cases}	179	172	162	156	
<7.0 μg/dL	1.00 (reference)	1.05 (0.80,1.37)	0.92 (0.69,1.24)	1.04 (0.77,1.42)	1.04 (0.93, 1.17)
Serum retinol					
n_{cases}	42	60	62	76	
Above 75th percentile (> 69 μg/dL)	1.00 (reference)	0.84 (0.44,1.61)	0.77 (0.45,1.32)	0.72 (0.36,1.42)	0.94 (0.75,1.16)
n_{cases}	159	158	152	135	
At or below 75th percentile (≤ 69 μg/dL)	1.00 (reference)	1.06 (0.76,1.48)	0.99 (0.67,1.44)	1.01 (0.68,1.49)	1.05 (0.89,1.24)
Preformed vitamin A supplement use					
n_{cases}	26	46	52	63	
Yes	1.00 (reference)	0.90 (0.35,2.30)	0.67 (0.27,1.62)	0.73 (0.28,1.94)	0.93 (0.71,1.21)
n_{cases}	175	172	162	148	
No	1.00 (reference)	0.97 (0.72,1.30)	1.01 (0.73,1.39)	0.94 (0.67,1.32)	1.04 (0.90,1.19)
Cardiovascular disease					
n_{cases}	449	433	430	403	
Model 1	1.00 (reference)	0.75 (0.64,0.88)	0.63 (0.54,0.75)	0.65 (0.55,0.77)	0.87 (0.81,0.93)
Model 2	1.00 (reference)	0.80 (0.68,0.95)	0.72 (0.61,0.85)	0.74 (0.63,0.88)	0.91 (0.85,0.98)
Model 3	1.00 (reference)	0.84 (0.71,1.00)	0.74 (0.63,0.86)	0.79 (0.67,0.94)	0.92 (0.86,0.98)
Serum retinyl esters					
n_{cases}	79	127	121	139	
≥7.0 μg/dL	1.00 (reference)	0.84 (0.56,1.26)	0.73 (0.47,1.14)	0.87 (0.59,1.30)	0.98 (0.86,1.10)
n_{cases}	370	306	309	264	
<7.0 μg/dL	1.00 (reference)	0.84 (0.68,1.04)	0.72 (0.57,0.91)	0.76 (0.61,0.95)	0.90 (0.82,0.98)
Serum retinol					
n_{cases}	118	153	154	184	
Above 75th percentile (> 69 μg/dL)	1.00 (reference)	0.85 (0.59,1.22)	0.58 (0.41,0.81)	0.62 (0.44,0.89)	0.88 (0.78,0.99)
n_{cases}	331	280	276	219	
At or below 75th percentile (≤ 69 μg/dL)	1.00 (reference)	0.82 (0.66,1.01)	0.83 (0.68,1.01)	0.91 (0.69,1.20)	0.94 (0.86,1.03)
Preformed vitamin A supplement use					
n_{cases}	50	84	104	125	
Yes	1.00 (reference)	0.63 (0.39,1.03)	0.55 (0.34,0.90)	0.71 (0.41,1.24)	0.97 (0.84,1.11)
n_{cases}	399	349	326	278	
No	1.00 (reference)	0.92 (0.76,1.12)	0.82 (0.67,1.01)	0.81 (0.64,1.02)	0.91 (0.83,0.99)
Non-cancer-non-cardiovascular disease					
n_{cases}	328	330	331	295	

Model 1	1.00 (reference)	0.73 (0.58,0.93)	0.65 (0.49,0.86)	0.59 (0.43,0.80)	0.87 (0.79,0.95)
Model 2	1.00 (reference)	0.80 (0.63,1.01)	0.74 (0.56,0.97)	0.63 (0.47,0.84)	0.88 (0.81,0.97)
Model 3	1.00 (reference)	0.82 (0.65,1.04)	0.74 (0.57,0.97)	0.67 (0.51,0.88)	0.89 (0.82,0.97)
Serum retinyl esters					
n_{cases}	47	89	84	92	
≥7.0 μg/dL	1.00 (reference)	0.90 (0.53,1.55)	0.70 (0.40,1.21)	0.81 (0.42,1.55)	0.98 (0.83,1.16)
n_{cases}	281	241	247	203	
<7.0 μg/dL	1.00 (reference)	0.81 (0.62,1.05)	0.76 (0.55,1.03)	0.64 (0.47,0.86)	0.87 (0.78,0.96)
Serum retinol					
n_{cases}	76	100	110	127	
Above 75th percentile (> 69 μg/dL)	1.00 (reference)	0.79 (0.48,1.30)	0.70 (0.45,1.09)	0.63 (0.35,1.11)	0.86 (0.75,0.98)
n_{cases}	252	230	221	168	
At or below 75th percentile (≤ 69 μg/dL)	1.00 (reference)	0.83 (0.64,1.07)	0.72 (0.54,0.97)	0.65 (0.51,0.84)	0.90 (0.81,0.99)
Preformed vitamin A supplement use					
n_{cases}	34	67	82	98	
Yes	1.00 (reference)	0.85 (0.53,1.36)	0.55 (0.33,0.92)	0.52 (0.30,0.89)	0.79 (0.65,0.95)
n_{cases}	294	263	249	197	
No	1.00 (reference)	0.79 (0.61,1.03)	0.81 (0.60,1.08)	0.71 (0.52,0.97)	0.93 (0.84,1.04)

[1] n_{cases}, number of deaths; Model 1 was adjusted for age, sex, race/ethnicity, and season; Model 2 was adjusted for variables of model 1 and for lifestyle and socioeconomic factors (poverty-income ratio, body mass index, physical activity, smoking status, alcohol consumption, education and hormone replacement therapy); Model 3 was adjusted for variables of model 2 and for potential intermediates (hypertension, diabetes mellitus, hypercholesterolemia, history of myocardial infarction, history of stroke, and history of cancer; All P-values for interaction were >0.05

[2] Per 10 ng/mL increase in 25(OH)D entered as a continuous variable

All estimates were weighted to account for the complex survey design of NHANES III

FIGURE 1
Association between circulating 25(OH)D concentration and all-cause mortality by vitamin A markers in NHANES III (1988–2006); Results are reported as hazard ratios with 95% confidence intervals (CI) per 10 ng/mL increase of 25(OH)D concentration (horizontal bar), adjusted for all variables in model 3[1]

(Figure 1 from jpg/png file: *Fig1.jpg or Fig 1.png. MS Excel was used to create figure 1.*)

[1]Model 3 was adjusted for age, sex, race/ethnicity, and season, lifestyle and socioeconomic factors (poverty-income ratio, body mass index, physical activity, smoking status, alcohol consumption, education and hormone replacement therapy) and for potential intermediates (hypertension, diabetes mellitus, hypercholesterolemia, history of myocardial infarction, history of stroke, and history of cancer). All estimates were weighted to account for the complex survey design of NHANES III


Subgroup
Hazard ratio for all-cause mortality (95% CI)
P value for interaction
All participants, model 3
Q4
Q3
Q2
Q1
Serum retinyl esters <7.0 µg/dL
Q4
Q3
Q2
Q1
Serum retinyl esters ≥7.0 µg/dL
Q4
Q3
Q2
Q1
0.96
Serum retinol ≤69 µg/dL
Q4
Q3
Q2
Q1
Serum retinol >69 µg/dL
Q4
Q3
Q2
Q1
0.16
No preformed vitamin A supplement use
Q4
Q3
Q2
Q1
Any preformed vitamin A supplement use
Q4
Q3
Q2
Q1
0.06
Preformed vitamin A intake from supplements >5000 IU
Q4
Q3
Q2
Q1
Preformed vitamin A intake from supplements ≤5000 IU
Q4
Q3
Q2
Q1
0.53
0
0.5
1
1.5
2
2.5
3
3.5
4